Cancel anytime
Cactus Acquisition Corp. 1 Limited Warrant (CCTSW)CCTSW
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/25/2024: CCTSW (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -53.85% | Upturn Advisory Performance 1 | Avg. Invested days: 16 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 10/25/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -53.85% | Avg. Invested days: 16 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 10/25/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD |
Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) - |
Volume (30-day avg) 23304 | Beta 0.01 |
52 Weeks Range 0.01 - 0.13 | Updated Date 11/3/2024 |
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) - | Volume (30-day avg) 23304 | Beta 0.01 |
52 Weeks Range 0.01 - 0.13 | Updated Date 11/3/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -2.37% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA - |
Shares Outstanding - | Shares Floating 1732358 |
Percent Insiders - | Percent Institutions - |
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 1732358 |
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating - | Target Price - | Buy - | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
Cactus Acquisition Corp. 1 Limited Warrant (CACTW) Overview
Company Profile
Detailed History and Background:
- Cactus Acquisition Corp. 1 Limited Warrant (CACTW) is a publicly traded warrant issued by Cactus Acquisition Corp. 1 (CACT), a special purpose acquisition company (SPAC) formed in March 2021.
- SPACs are blank-check companies that raise capital through an IPO to acquire a private company within a specified timeframe.
- CACT raised $172.5 million in its IPO and set a two-year deadline to complete an acquisition.
- In July 2023, CACT announced its merger agreement with Nkarta, a clinical-stage biopharmaceutical company focusing on developing natural killer cell-based therapies for cancer.
Description of Core Business Areas:
- CACTW does not have any independent business operations.
- Its value is derived solely from the potential for CACT to acquire a target company and the warrant's entitlement to receive shares of the combined entity upon completion of the merger.
Overview of Leadership and Corporate Structure:
- CACT is led by Chairman and CEO Leonard Schleifer, the co-founder of regenerative medicine company Regeneron Pharmaceuticals.
- The board of directors also includes prominent figures like former FBI Director James Comey and former Celgene CEO Robert Bradway.
Top Products and Market Share:
- CACTW itself is not a product.
- The value proposition of CACTW is the potential for its holders to participate in the upside of Nkarta's future success.
- As of November 2023, Nkarta is a private company with no products approved for sale.
Total Addressable Market:
- The global market for cancer treatments is estimated to be worth over $150 billion and is expected to grow significantly in the coming years.
- Nkarta's specific focus on natural killer cell therapy targets a segment of the market with high unmet medical needs.
Financial Performance:
- As a warrant, CACTW does not have independent financial statements.
- Its value is tied to the stock price of CACT and the potential success of the merged entity with Nkarta.
- CACT's stock price has declined significantly since its IPO, reflecting the market's uncertainty about the future of the SPAC and its pending acquisition.
Dividends and Shareholder Returns:
- CACTW does not pay dividends.
- Shareholder returns are dependent on the performance of CACT stock and the potential success of the merged entity with Nkarta.
Growth Trajectory:
- CACTW's growth prospects are tied to the future performance of Nkarta.
- Nkarta is currently in the clinical trial stage for its lead product candidate, NKX101, for the treatment of acute myeloid leukemia.
- The success of clinical trials and subsequent regulatory approval will be crucial for Nkarta's growth and future value.
Market Dynamics:
- The SPAC market has experienced significant volatility in recent years.
- The performance of CACTW will depend on market sentiment towards SPACs in general and the specific outlook for the combined entity with Nkarta.
- The biopharmaceutical industry is highly competitive, with numerous companies developing similar therapies.
Competitors:
- Key competitors in the natural killer cell therapy space include:
- Fate Therapeutics (FATE)
- Carisma Therapeutics (CTRX)
- NNK Therapeutics (NNK)
- These companies are all at similar stages of development and vying for market share in this rapidly evolving field.
Potential Challenges and Opportunities:
Challenges:
- The clinical development process for NKX101 is complex and carries inherent risks.
- Regulatory approval from the FDA is not guaranteed.
- Intense competition from other players in the NK cell therapy space.
Opportunities:
- The potential for NKX101 to address a significant unmet medical need.
- Nkarta's strong scientific team and promising preclinical data.
- The potential for strategic partnerships with larger pharmaceutical companies.
AI-Based Fundamental Rating:
Rating: 5/10
Justification:
- CACTW's value proposition is based on the future potential of Nkarta.
- Nkarta's NKX101 has promising preclinical data, but clinical development carries significant risks.
- The company is in a highly competitive market with established players.
- The overall market sentiment towards SPACs is uncertain.
Disclaimer:
This report is based on publicly available information and does not constitute financial advice. It is essential to conduct thorough research and consult with a qualified financial professional before making any investment decisions.
Sources:
- U.S. Securities and Exchange Commission (SEC) filings
- Nkarta website
- Competitor company websites
- Industry research reports
Please note: This report is based on information available as of November 17, 2023. As this is a rapidly evolving situation, it is crucial to stay up-to-date with the latest developments.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cactus Acquisition Corp. 1 Limited Warrant
Exchange | NASDAQ | Headquaters | Cranbury, NJ, United States |
IPO Launch date | 2022-01-03 | CEO | - |
Sector | Financial Services | Website | https://cactusac1.com |
Industry | Shell Companies | Full time employees | - |
Headquaters | Cranbury, NJ, United States | ||
CEO | - | ||
Website | https://cactusac1.com | ||
Website | https://cactusac1.com | ||
Full time employees | - |
Cactus Acquisition Corp. 1 Limited does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the emerging technology sector. The company was incorporated in 2021 and is based in Cranbury, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.